Related Experiment Videos
Recombinant activated factor VII in paediatric cardiac surgery
Jonathan R Egan1, Ahti Lammi, David N Schell
1Paediatric Intensive Care Unit, The Children's Hospital at Westmead, Locked Bag 4001 Westmead, NSW 2145, Sydney, Australia. jonathoe@chw.edu.au
Intensive Care Medicine
|December 20, 2003
Summary
Recombinant activated factor VII effectively achieved haemostasis in pediatric cardiac surgery patients. This study found good outcomes and no adverse events when using recombinant activated factor VII for bleeding control.
Area of Science:
- Cardiovascular Surgery
- Paediatric Intensive Care
- Haematology
Background:
- Excessive bleeding is a significant complication in paediatric cardiac surgery.
- Managing haemostasis in paediatric cardiac surgical patients requires careful consideration.
- Recombinant activated factor VII (rFVIIa) is a potential option for refractory bleeding.
Purpose of the Study:
- To review the use of recombinant activated factor VII (rFVIIa) in paediatric cardiac surgery.
- To evaluate the efficacy and safety of rFVIIa in this patient population.
Main Methods:
- Retrospective chart review of paediatric cardiac surgical patients.
- Inclusion criteria: patients receiving rFVIIa for excessive bleeding.
- rFVIIa administered at 180 microg/kg, with potential repeat dose.
Main Results:
- Six paediatric patients received rFVIIa for persistent bleeding post-cardiac surgery.
- All six patients achieved haemostasis following rFVIIa administration.
- No adverse events were recorded during the study period.
Conclusions:
- Recombinant activated factor VII is effective in achieving haemostasis in paediatric cardiac surgery.
- rFVIIa demonstrated a favourable safety profile in this cohort.
- rFVIIa represents a viable therapeutic option for managing bleeding in paediatric cardiac surgical patients.